Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Operating Expenses (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Operating Expenses for 16 consecutive years, with $17.6 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 58.92% to $17.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $66.9 million through Dec 2025, up 24.23% year-over-year, with the annual reading at $66.9 million for FY2025, 24.23% up from the prior year.
  • Operating Expenses for Q4 2025 was $17.6 million at Niagen Bioscience, roughly flat from $17.7 million in the prior quarter.
  • The five-year high for Operating Expenses was $19.4 million in Q3 2021, with the low at $11.1 million in Q4 2024.
  • Average Operating Expenses over 5 years is $15.4 million, with a median of $15.1 million recorded in 2023.
  • The sharpest move saw Operating Expenses crashed 31.65% in 2022, then skyrocketed 58.92% in 2025.
  • Over 5 years, Operating Expenses stood at $16.2 million in 2021, then decreased by 16.83% to $13.5 million in 2022, then dropped by 2.64% to $13.1 million in 2023, then dropped by 15.41% to $11.1 million in 2024, then skyrocketed by 58.92% to $17.6 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $17.6 million, $17.7 million, and $17.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.